← Back to Search

Virus Vaccine

COVAC-2 for COVID-19

Phase 1
Waitlist Available
Research Sponsored by University of Saskatchewan
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 365 days
Awards & highlights

Study Summary

This trial is testing a new vaccine called COVAC-2, which contains a portion of the SARS-CoV-2 spike protein. The purpose of the study is to see if the vaccine is safe and effective in preventing severe COVID-19 illness. The study will involve two groups of people, one group receiving the vaccine and the other receiving a placebo. The study will also include an open-label exploratory study arm to evaluate safety and immunogenicity of a single COVAC-2 dose in previously SARS-CoV-2-infected individuals.

Eligible Conditions
  • Double Vaccinated for COVID-19
  • COVID-19

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 365 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 365 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Assessment of the safety and tolerability of COVAC-2 booster vaccine in generally healthy volunteers
Secondary outcome measures
To assess the immune response induced by COVAC-2 booster vaccine, as measured by cell immune response markers up to Day 365.
To assess the spike binding and neutralizing response induced by COVAC-2 booster vaccine
Other outcome measures
Explore the effect of the age group, number of previous COVID-19 vaccine doses and type of previous COVID-19 vaccine on immune response

Trial Design

3Treatment groups
Experimental Treatment
Placebo Group
Group I: COVAC-2 25 µg groupExperimental Treatment1 Intervention
20 healthy adults ≥18 years of age receive the vaccine on Day 0
Group II: COVAC-2 10 µg groupExperimental Treatment1 Intervention
20 healthy adults ≥18 years of age receive the vaccine on Day 0.
Group III: Placebo ControlPlacebo Group1 Intervention
20 healthy adults ≥18 years of age receive a dose of normal saline (placebo) on Day 0.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
COVAC-2
2021
Completed Phase 1
~70

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Government of CanadaOTHER_GOV
12 Previous Clinical Trials
2,307 Total Patients Enrolled
Government of SaskatchewanOTHER_GOV
4 Previous Clinical Trials
258 Total Patients Enrolled
Vaccine Formulation Institute (VFI)UNKNOWN
2 Previous Clinical Trials
211 Total Patients Enrolled

Media Library

COVAC-2 (Virus Vaccine) Clinical Trial Eligibility Overview. Trial Name: NCT05226702 — Phase 1
Double Vaccinated for COVID-19 Research Study Groups: COVAC-2 10 µg group, COVAC-2 25 µg group, Placebo Control
Double Vaccinated for COVID-19 Clinical Trial 2023: COVAC-2 Highlights & Side Effects. Trial Name: NCT05226702 — Phase 1
COVAC-2 (Virus Vaccine) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05226702 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this experiment accepting new participants?

"The information on clinicialtrials.gov indicates that this trial is actively recruiting participants. The initial posting date was July 22nd 2022 and the most recent update happened on August 24th 2022."

Answered by AI

What is the size of this clinical trial's participant population?

"Affirmative. The official records on clinicaltrials.gov indicate that the trial, which opened for recruitment in July of 2022, is still recruiting participants from 3 sites with a total enrolment target of 380 individuals."

Answered by AI
~22 spots leftby Mar 2025